Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5589-5601
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Figure 1 Flowchart of the selection of gastric cancer patients.
5-FU: 5-fluorouracil; NSR: Non-sustained-release.
- Citation: Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
- URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5589